Growth Metrics

OptimizeRx (OPRX) Debt to Equity (2019 - 2026)

OptimizeRx's Debt to Equity history spans 5 years, with the latest figure at $0.2 for Q4 2025.

  • On a quarterly basis, Debt to Equity fell 28.65% to $0.2 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.2, a 28.65% decrease, with the full-year FY2025 number at $0.2, down 28.65% from a year prior.
  • Debt to Equity hit $0.2 in Q4 2025 for OptimizeRx, down from $0.23 in the prior quarter.
  • Over the last five years, Debt to Equity for OPRX hit a ceiling of $0.31 in Q3 2024 and a floor of $0.2 in Q4 2025.
  • Historically, Debt to Equity has averaged $0.27 across 3 years, with a median of $0.28 in 2024.
  • Biggest five-year swings in Debt to Equity: dropped 2.03% in 2024 and later fell 28.65% in 2025.
  • Tracing OPRX's Debt to Equity over 3 years: stood at $0.29 in 2023, then decreased by 2.03% to $0.28 in 2024, then fell by 28.65% to $0.2 in 2025.
  • Business Quant data shows Debt to Equity for OPRX at $0.2 in Q4 2025, $0.23 in Q3 2025, and $0.24 in Q2 2025.